Venus Remedies gains on unveiling Taxedol in India

Venus Remedies is currently trading at Rs. 208.70, up by 0.40 points or 0.19% from its previous closing of Rs. 208.30 on the BSE.

The scrip opened at Rs. 206.00 and has touched a high and low of Rs. 213.70 and Rs. 206.00 respectively. So far 7162 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 275.95 on 28-Jul-2011 and a 52 week low of Rs. 141.05 on 22-Dec-2011.

Last one week high and low of the scrip stood at Rs. 218.00 and Rs. 206.00 respectively. The current market cap of the company is Rs. 202.63 crore.

The promoters holding in the company stood at 34.71% while Institutions and Non-Institutions held 14.42% and 50.87% respectively. 

Venus Remedies, a leading research based global pharmaceutical company has introduced for the first time a nanotechnology based ‘Ready-to-Use’ Single Vial Docetaxel in the domestic market under the brand name ‘Taxedol’. Taxedol is ready to use single vial formulation available in three strengths 20mg/0.5 ml, 80mg/2 ml and 120mg/3ml.

Taxedol (Docetaxel) is a single unit stable, pharmaceutical formulation which has lesser impurities in comparison to innovator product. This one vial formulation of Docetaxel will not only make the administration of the drug easier by introducing the premix solution but at the same time will provide enhanced safety to patients and para-medical staff. Furthermore, the nano-scale size of the formulation results in improved penetration, higher efficacy, improved safety and lesser side effects.

A semi-synthetic cytostatic taxane analogue, Docetaxel is considered as one of the most effective and successful oncology products, which is used mainly for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head and neck cancer and ovarian cancer.

Taxedol, a ‘Ready-to-Use’ single vial will not only weed out the competition from other players in the market but the company is hopeful of capturing significant share in Rs 1,500 crore Indian Cancer Drug Industry, which is speculated to show a steady growth over the coming few years.